166 related articles for article (PubMed ID: 9096663)
1. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
Perez-Soler R; Neamati N; Zou Y; Schneider E; Doyle LA; Andreeff M; Priebe W; Ling YH
Int J Cancer; 1997 Mar; 71(1):35-41. PubMed ID: 9096663
[TBL] [Abstract][Full Text] [Related]
2. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
Perez-Soler R; Ling YH; Zou Y; Priebe W
Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162
[TBL] [Abstract][Full Text] [Related]
4. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
[TBL] [Abstract][Full Text] [Related]
5. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
8. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
9. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells.
Ling YH; Zou Y; Priebe W; Perez-Soler R
Int J Cancer; 1995 May; 61(3):402-8. PubMed ID: 7729954
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
11. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Giaccone G; van Ark-Otte J; Rubio GJ; Gazdar AF; Broxterman HJ; Dingemans AM; Flens MJ; Scheper RJ; Pinedo HM
Int J Cancer; 1996 Jun; 66(6):760-7. PubMed ID: 8647646
[TBL] [Abstract][Full Text] [Related]
12. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Lee JS; Scala S; Matsumoto Y; Dickstein B; Robey R; Zhan Z; Altenberg G; Bates SE
J Cell Biochem; 1997 Jun; 65(4):513-26. PubMed ID: 9178101
[TBL] [Abstract][Full Text] [Related]
13. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.
Berger W; Hauptmann E; Elbling L; Vetterlein M; Kokoschka EM; Micksche M
Int J Cancer; 1997 Mar; 71(1):108-15. PubMed ID: 9096673
[TBL] [Abstract][Full Text] [Related]
14. Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues.
Kubota T; Furukawa T; Tanino H; Suto A; Otan Y; Watanabe M; Ikeda T; Kitajima M
Breast Cancer; 2001; 8(4):333-8. PubMed ID: 11791127
[TBL] [Abstract][Full Text] [Related]
15. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro.
Khodadadian M; Leroux ME; Auzenne E; Ghosh SC; Farquhar D; Evans R; Spohn W; Zou Y; Klostergaard J
Lung Cancer; 2009 Oct; 66(1):48-57. PubMed ID: 19195736
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
17. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.
Gaj CL; Anyanwutaku I; Chang YH; Cheng YC
Biochem Pharmacol; 1998 Apr; 55(8):1199-211. PubMed ID: 9719474
[TBL] [Abstract][Full Text] [Related]
18. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
[TBL] [Abstract][Full Text] [Related]
19. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
20. Modulation of doxorubicin cytotoxicity by ethacrynic acid.
Awasthi S; Singhal SS; He N; Chaubey M; Zimniak P; Srivastava SK; Singh SV; Awasthi YC
Int J Cancer; 1996 Nov; 68(3):333-9. PubMed ID: 8903475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
